U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H23N5O5
Molecular Weight 449.4592
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CH-1504

SMILES

NC1=NC(N)=C2C=C(CCC3=CC=C(C=C3)C(=O)NC(CC(=C)C(O)=O)C(O)=O)C=CC2=N1

InChI

InChIKey=NAWXUBYGYWOOIX-UHFFFAOYSA-N
InChI=1S/C23H23N5O5/c1-12(21(30)31)10-18(22(32)33)26-20(29)15-7-4-13(5-8-15)2-3-14-6-9-17-16(11-14)19(24)28-23(25)27-17/h4-9,11,18H,1-3,10H2,(H,26,29)(H,30,31)(H,32,33)(H4,24,25,27,28)

HIDE SMILES / InChI

Molecular Formula C23H23N5O5
Molecular Weight 449.4592
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 12:12:56 UTC 2023
Edited
by admin
on Sat Dec 16 12:12:56 UTC 2023
Record UNII
8Y3RH62XPB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CH-1504
Common Name English
AA-243
Code English
M-TREX
Common Name English
MOBILETREX
Common Name English
CH 1504
Code English
TRIDAM
Common Name English
2-((4-(2-(2,4-DIAMINOQUINAZOLIN-6-YL)ETHYL)BENZOYL)AMINO)-4-METHYLENE-PENTANEDIOIC ACID
Systematic Name English
GLUTAMIC ACID, N-(4-(2-(2,4-DIAMINO-6-QUINAZOLINYL)ETHYL)BENZOYL)-4-METHYLENE-
Systematic Name English
Code System Code Type Description
FDA UNII
8Y3RH62XPB
Created by admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
PRIMARY
CAS
238074-89-0
Created by admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
PRIMARY
CLINICAL_TRIALS.GOV
CH-1504
Created by admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
PRIMARY Official Title: A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid ArthritisPurpose: The purpose of this trial is to assess the clinical effect of CH-1504 at doses of 0.25, 0.5 and 1.0 mg per day in patients with active rheumatoid arthritis by determining the proportion of patients achieving an American College of Rheumatology (ACR) 20% improvement response.
PUBCHEM
9846537
Created by admin on Sat Dec 16 12:12:56 UTC 2023 , Edited by admin on Sat Dec 16 12:12:56 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Demographic characteristics were similar in all treatment groups: mean age 54.3 +/- 11.4 years, female sex 87%, mean baseline DAS28 6.6 +/- 0.9. At Week 12, CH-1504 demonstrated comparable efficacy compared to MTX as measured by ACR20, DAS28, and ACR composite core-set measures, including tender and swollen joints. No dose-response relationship was observed. Adverse events across treatment groups were mild. Liver enzyme levels increased from baseline to Week 16 in the MTX group, with qualitatively lesser increases in the CH-1504 groups. Two patients in the MTX group withdrew because of gastrointestinal-related adverse events. CH-1504 appeared safe and well tolerated at all dose levels. CONCLUSION: CH-1504 has comparable efficacy to MTX and is safe and well tolerated. Metabolically stable antifolates are a promising therapeutic option that warrants further study.
ACTIVE MOIETY
Class: Anti-neoplastic; Mechanism of Action: Tetrahydrofolate dehydrogenase inhibitor; Highest Development Phases: Discontinued for Cancer, Inflammatory bowel diseases, Psoriasis, and Rheumatoid arthritis; Most Recent Events: 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S, 22 Oct 2009 Interim efficacy and adverse events data from a phase II trial in Rheumatoid arthritis presented at the the 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2009), 18 Mar 2009 Interim efficacy & adverse events data from a phase II trial in Rheumatoid arthritis released by Chelsea Therapeutics